Regnerative medicine company $OCC has announced a second, specialist distributorship for Canada, completing 100% market coverage of this market for its nerve repair product, Remplir, which it says is worth US$75m (Note: they've previously said ANZ is worth US$35m, so the procedures must be a lot more pricey in Canada.)
ASX Announcement
Not really price sensitive, but good news nonetheless.In its first year in ANZ Remplir did about AUD0.4-0.5m. All eyes, however, are on the lucrative US market. Perhaps there might be an interim update at tomorrow's AGM on progress?
Disc: Held (RL 3%)